Haemonetics Corporation (HAE)
Return on total capital
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | — | 168,361 | 156,033 | 80,750 | 57,963 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 820,836 | 959,959 | 817,997 | 749,424 | 731,670 |
| Return on total capital | 0.00% | 17.54% | 19.08% | 10.77% | 7.92% |
March 31, 2025 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $820,836K)
= 0.00%
Haemonetics Corporation's return on total capital has shown a positive trend over the years, starting at 7.92% as of March 31, 2021, and increasing to 10.77% by March 31, 2022. The significant improvement continued, reaching 19.08% by March 31, 2023, and then slightly decreasing to 17.54% as of March 31, 2024. However, the ratio for March 31, 2025 is not available. Overall, the company has demonstrated a generally improving ability to generate returns relative to its total capital invested, which indicates positive performance in utilizing its resources efficiently.
Peer comparison
Mar 31, 2025